Skip to content

Incyte INCY Current Debt

Current Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.03B-78.2%
Pfizer logo
PfizerPFE
$3.86B+3.0%
Gilead Sciences logo
Gilead SciencesGILD
$1.31B-53.2%
Geron logo
GeronGERN
$11.93M
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350M+4.2%
AbbVie logo
AbbVieABBV
$0-100%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.96B+73.3%
Enterprise value$22.01B+68.5%
P/E16.1×-1.1×
P/S4.5×+1.2×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's current debt?
Incyte (INCY) reported current debt of $4.26M in Q2 2026.
How has Incyte's current debt changed year-over-year?
Incyte's current debt decreased by 4.8% year-over-year, from $4.48M to $4.26M.
What is the long-term trend for Incyte's current debt?
Over 5 years (2020 to 2025), Incyte's current debt has grown at a 14.6% compound annual growth rate (CAGR), from $2.28M to $4.52M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.